This page was last updated on 21 March 2018

Click here to 
Print this page

Biography finder

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

 

 

Index of first names

Douglas Pharmaceuticals 

 

 

 

 

 

Douglas Pharmaceuticals Ltd was established in 1967 by Sir Graeme Douglas and is the largest New Zealand owned pharmaceuticals manufacturer of quality pharmaceuticals.

 

 Employing around 470 people in New Zealand, Douglas has manufacturing plants in Auckland and Fiji. Douglas exports 65% of manufactured product to international markets and has a strong presence in NZ retail pharmacy. The laboratories and quality systems meet FDA requirements for product release into the USA.

 

Douglas Pharmaceuticals Ltd’s current annual research and development spend of $19 million is focused on new products for local and export markets. Douglas Pharmaceuticals Ltd is an excellent example of New Zealand's knowledge economy in action.

 

 

Any contributions will be gratefully accepted



 

 

Errors and Omissions

The Forum

What's new?

We are looking for your help to improve the accuracy of The Douglas Archives.

If you spot errors, or omissions, then please do let us know

Contributions

Many articles could benefit from re-writing. Can you help?


 

If you have met a brick wall with your research, then posting a notice in the Douglas Archives Forum may be the answer. Or, it may help you find the answer!

You may also be able to help others answer their queries.

Visit the Douglas Archives Forum.

 

We try to keep everyone up to date with new entries, via our What's New section on the home page.

We also use the Community Network to keep researchers abreast of developments in the Douglas Archives.

 
 
 


Back to top

 



The content of this website is a collection of materials gathered from a variety of sources, some of it unedited.

The webmaster does not intend to claim authorship, but gives credit to the originators for their work.

As work progresses, some of the content may be re-written and presented in a unique format, to which we would then be able to claim ownership.

Discussion and contributions from those more knowledgeable is welcome.

Contact Us

Last modified: Wednesday, 18 July 2018